Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

Summary

450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatments. Group A：Subjects with Bencycloquidium Bromide Nasal Spray, Group B：Subjects with Mometasone Furoate Aqueous Nasal Spray, Group C：Subjects with Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray.The main purpose of the trial is to evaluate the efficacy of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.

Timeline

Start

2021-06-16

Primary completion

2024-04-30

Completion

2024-06-30

Outcome

Met primary endpoint

paper compared with MFNS (least-squares mean difference, -0.27; 95% CI, -0.44 to -0.09; P = .004). PMID 39746515 ↗

paper Bencycloquidium bromide was superior to MFNS in reducing daily runny nose symptoms. PMID 39746515 ↗

Publications

• Li X, Wang X, Yang Q, Chen J, Tian H, Lu M, Ma T, Zhang Y, Zhou Y, Xia J, Cheng L, Zhang Y, Zhang L. A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis. J Allergy Clin Immunol Pract. 2025 Mar;13(3):670-679.e3. doi: 10.1016/j.jaip.2024.12.035. Epub 2024 Dec 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BENCYCLOQUIDIUM	Small molecule	90 ug	Intranasal
Subject	Mometasone furoate	Other / unclassified	50 ug	Intranasal

Indications